98 StrokeMatters . . . . . . . . . . . . . . . . . . . . . October 1998 clinical trials is the Stroke Institute web page. Patients eligible for this trial are greater than 18 years of age, with suspected MCA territory within six hours of onset. IA delivery of urokinase. This is a UPMC Health System Stroke Institute protocol used for patients with occlusion of a major cerebral vessel.
All patients receive the drug, and each patient is followed for clinical outcomes.
Eligible patients are greater than 18 years of age, and have an acute ischemic stroke within six hours. In June, it was announced that Lubeluzole did not reach its targeted primary and secondary endpoints, therefore, all further development of this product has been stopped. The UPMC Health System Stroke Institute was the highest enrolling site in the trial. Hospitals that made that happen were UPMC Presbyterian, UPMC Lee Regional, The Washington Hospital, UPMC Passavant, and UPMC Horizon. Phase 3 study includes ischemic, hemorrhagic, and rt- PA treated patients.